小规模生物反应器市场－全球产业规模、份额、趋势、机会和预测：按最终用户、产品、地区和竞争对手划分，2021-2031年

全球小型生物反应器市场预计将从 2025 年的 16.4 亿美元成长到 2031 年的 20.9 亿美元，复合年增长率为 4.12%。

该领域涵盖工作量较小的紧凑型培养系统，专为实验室研究、製程开发和高通量筛检应用而设计。主要成长要素包括对经济高效的研究工作流程日益增长的需求，以及加速新型生物製药商业化的迫切需求。随着製药公司专注于快速细胞株筛检以缩短研发週期，对早期工具的投资显着增加。根据欧洲製药工业协会联合会（EFPIA）的数据，预计到2024年，欧洲以研发为基础的製药业将在研发方面投入约550亿欧元，这凸显了支撑这些技术应用的雄厚资金支持。

儘管市场成长势头强劲，但在将实验成果转化为商业化生产方面仍面临诸多挑战。小型容器内复杂的流体动态和混合特性通常与工业储槽截然不同，导致数据不一致，并使技术转移变得复杂。这些技术限制要求製造商进行严格的检验研究，以确保在实验室环境中确定的参数能够在大规模生产环境中重现。此类要求可能会无意中延误生产进度，并阻碍市场的顺利扩张。

市场驱动因素

生物製药和生物相似药研发管线的显着成长是推动小规模生物反应器应用的主要动力。随着产业转向单株抗体和重组蛋白等多样化治疗方法，对高通量製程开发工具的需求日益增长，这些工具能够在药物研发早期阶段实现实验并行化并优化细胞培养条件。研发管线活动的增加需要稳健的小体积系统来筛检克隆并在放大生产前确定关键程式参数。根据美国食品药物管理局（FDA）于2025年1月发布的《2024年新药核准年度报告》，该机构在2024年核准了50种新药，这凸显了大量需要进行广泛上市前测试的新型分子。此外，正如BioSpace在2025年报告的那样，2024年全球製药研发支出将达到近2,880亿美元，为实验室采用先进的桌上型系统提供了必要的资金。

同时，对细胞和基因治疗研究投入的增加正在改变小规模生物反应器市场。与生物製药不同，细胞和基因疗法的工作流程通常依赖规模化而非规模化策略，这使得小容量反应器对于患者特异性自体疗法和病毒载体的生产至关重要。由于这些先进治疗方法的复杂性，需要对小规模培养环境进行精确控制，以确保产品在整个临床阶段的安全性和一致性。该领域的经济实力直接影响设备的采购。根据再生医学联盟于2025年1月发布的《产业趋势简报》，2024年细胞和基因治疗领域的投资金额达152亿美元，呈现显着的年增长。这将支持为这些标靶治疗引入专用生物反应器。

市场挑战

全球小规模生物反应器市场面临的一大障碍是难以将实验室数据可靠地推广到商业化生产。与大型工业槽相比，小型培养系统在流体动态、混合效率和剪切应力分布等方面往往表现出截然不同的特性。这些物理差异导致针对小规模容器最佳化的生物过程在大体积下无法稳定运作。因此，製造商必须进行大量的检验研究，以确保小规模实验结果的可推广性，而这一过程削弱了最初推动这些技术应用的速度和效率优势。

製程转移可能性的不确定性为製药研发公司带来了巨大的财务风险，也使得它们在关键生产决策中不敢完全依赖小规模系统。当资料无法无缝外推时，企业将面临研发週期延长和后期失败的风险。根据欧洲製药工业协会联合会（EFPIA）预测，到2024年，新型化学品或生物製药的研发成本预计将达到约31.3亿欧元。鑑于如此巨大的资本风险，缺乏可保证的规模化生产能力迫使相关人员继续进行重迭的中试规模操作，最终限制了小规模生物反应器的整体市场渗透率。

市场趋势

人工智慧 (AI) 与数位双胞胎的融合正在变革小规模生物反应器的应用，将製程开发从纯粹的经验迭代转向预测建模。透过将桌上型反应器与In Silico模拟结合，并模拟各种培养条件，开发人员有效地减少了定义设计空间所需的物理实验数量。这种数位化分层有效地弥合了研发与商业化生产之间的技术鸿沟，使操作人员能够利用来自小型运行的即时数据来优化补料策略并预测放大后的性能。正如罗克韦尔自动化公司 2025 年 6 月发布的《智慧製造报告：生命科学版》所指出的，目前有 35% 的生命科学製造商正在考虑使用数位双胞胎技术和模拟工具来提升营运决策和预测能力。

同时，细胞和基因疗法研发的日益普及，对高度依赖小型系统的分散式生产能力提出了迫切需求。随着产业朝向自体移植和个人化医疗方向发展，传统的集中式供应链模式已无法满足需求，亟需能够在分散式和床边环境中可靠运作的小规模生物反应器。先进治疗方法的需求与现有基础设施之间的这种不匹配，正成为硬体创新的重要催化剂，促使供应商开发具有更高物流柔软性的系统。根据Cytiva于2025年10月发布的《全球生物製药韧性指数》，超过25%的生物製药高层表示，目前的供应链无法有效支持细胞和基因疗法等先进治疗方法，凸显了市场对高度适应性小规模生产技术的迫切需求。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：小规模生物反应器的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按最终用户划分（製药和生物製药公司、合约研究组织和合约生产组织、学术和研究机构）
  • 产品类别（可重复使用生物反应器（不锈钢生物反应器、玻璃生物反应器）、一次性生物反应器）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美小规模生物反应器市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲小规模生物反应器市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区小规模生物反应器市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲小规模生物反应器市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲小规模生物反应器市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章 全球小规模生物反应器市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Sartorius AG
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Danaher Corp.
• Lonza Group Ltd.
• Eppendorf SE
• Miltenyi Biotec India Pvt Ltd.
• Getinge AB
• Solaris Biotech USA, Inc.
• Infors AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Small-scale Bioreactors Market is projected to expand from a valuation of USD 1.64 Billion in 2025 to USD 2.09 Billion by 2031, reflecting a CAGR of 4.12%. This sector encompasses compact culture systems with reduced working volumes, specifically engineered for laboratory research, process development, and high-throughput screening applications. Key growth drivers include the rising demand for cost-effective research workflows and the urgent need to expedite the commercialization of new biologics. As pharmaceutical firms focus on rapid cell line screening to shorten development cycles, investment in early-stage tools has risen markedly. Data from the European Federation of Pharmaceutical Industries and Associations indicates that in 2024, the research-based pharmaceutical industry in Europe invested approximately 55,000 million euros in R&D, highlighting the significant financial backing supporting the adoption of these technologies.

Despite this strong growth trajectory, the market encounters a major obstacle related to scaling experimental results to commercial production. The intricate fluid dynamics and mixing properties within small vessels often vary fundamentally from those in industrial tanks, resulting in data discrepancies that complicate technology transfer. This technical constraint necessitates that manufacturers conduct rigorous validation studies to ensure that parameters defined in laboratory settings can be replicated in large-scale manufacturing environments. Such requirements can inadvertently delay production schedules and hinder seamless market expansion.

Market Driver

The substantial growth of the biopharmaceutical and biosimilars pipeline acts as a major driver for the adoption of small-scale bioreactors. With the industry pivoting toward diverse therapeutic modalities such as monoclonal antibodies and recombinant proteins, there is a heightened requirement for high-throughput process development tools capable of parallelizing experiments and optimizing cell culture conditions early in the drug development lifecycle. This increase in pipeline activity demands robust small-volume systems to screen clones and establish critical process parameters prior to scaling up. According to the FDA's '2024 New Drug Therapy Approvals Annual Report' released in January 2025, the agency approved 50 novel drugs in 2024, underscoring the significant volume of new molecules requiring extensive pre-commercial testing. Additionally, BioSpace reported in 2025 that global pharmaceutical R&D spending hit nearly $288 billion in 2024, providing the necessary capital for laboratories to procure advanced benchtop systems.

Simultaneously, escalating investment in cell and gene therapy research is transforming the small-scale bioreactor market. Unlike conventional biologics, cell and gene therapy workflows frequently rely on scale-out strategies rather than scale-up, rendering small-volume vessels essential for manufacturing patient-specific autologous therapies and viral vectors. The intricate nature of these advanced therapies necessitates precise control over culture environments at smaller scales to guarantee product safety and consistency throughout clinical phases. This sector's financial strength directly influences equipment purchasing; the Alliance for Regenerative Medicine's 'State of the Industry Briefing' from January 2025 noted that investment in the cell and gene therapy sector reached $15.2 billion in 2024, a significant annual increase that supports the deployment of specialized bioreactors for these targeted treatments.

Market Challenge

A critical barrier facing the Global Small-scale Bioreactors Market is the difficulty in reliably scaling experimental data from laboratory environments to commercial production. Compact culture systems frequently demonstrate fluid dynamics, mixing efficiencies, and shear stress profiles that differ fundamentally from those found in large-scale industrial tanks. These physical discrepancies generate a disconnect wherein biological processes that are optimized in small vessels do not perform consistently when scaled to higher volumes. As a result, manufacturers must perform extensive validation studies to confirm that findings from small-scale experiments are transferable, a process that undermines the speed and efficiency benefits that initially prompt the adoption of these technologies.

This uncertainty regarding process transferability introduces significant financial risk for pharmaceutical developers, making them hesitant to rely exclusively on small-scale systems for critical manufacturing decisions. When data cannot be seamlessly extrapolated, companies encounter extended development timelines and the possibility of late-stage failures. According to the European Federation of Pharmaceutical Industries and Associations, the estimated cost to research and develop a new chemical or biological entity was approximately 3,130 million euros in 2024. Given this substantial capital exposure, the lack of guaranteed scalability compels stakeholders to sustain redundant pilot-scale operations, thereby limiting the overall market penetration of small-scale bioreactors.

Market Trends

The integration of Artificial Intelligence and Digital Twins is transforming the application of small-scale bioreactors by moving process development from purely empirical iteration to predictive modeling. Developers are increasingly combining benchtop vessels with in silico replicas to simulate various culture conditions, effectively reducing the number of physical experiments needed to define design spaces. This digital layering enables operators to optimize feeding strategies and forecast scale-up performance using real-time data from small-volume runs, successfully bridging the technical divide between R&D and commercial manufacturing. As noted in Rockwell Automation's 'State of Smart Manufacturing Report: Life Sciences Edition' from June 2025, 35% of life sciences manufacturers are currently exploring digital twin technologies and simulation tools to improve their operational decision-making and predictive abilities.

Concurrently, the rising utilization of cell and gene therapy development is creating a critical demand for decentralized manufacturing capabilities heavily reliant on compact systems. As the industry progresses toward autologous and personalized treatments, traditional centralized supply chain models are becoming insufficient, necessitating small-scale bioreactors capable of reliable operation in distributed or bedside settings. This mismatch between advanced therapeutic requirements and existing infrastructure serves as a major catalyst for hardware innovation, driving vendors to create systems with enhanced logistical flexibility. According to Cytiva's 'Global Biopharma Resilience Index' published in October 2025, over 25% of biopharma executives indicated that their current supply chains cannot effectively support advanced modalities like cell and gene therapies, highlighting the urgent market need for adaptable small-scale production technologies.

Key Market Players

• Sartorius AG
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Danaher Corp.
• Lonza Group Ltd.
• Eppendorf SE
• Miltenyi Biotec India Pvt Ltd.
• Getinge AB
• Solaris Biotech USA, Inc.
• Infors AG

Report Scope

In this report, the Global Small-scale Bioreactors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Small-scale Bioreactors Market, By End user

• Pharmaceutical & Biopharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutes

Small-scale Bioreactors Market, By Product

• Reusable Bioreactors( Stainless Steel Bioreactors, Glass Bioreactors)
• Single-use Bioreactors

Small-scale Bioreactors Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Small-scale Bioreactors Market.

Available Customizations:

Global Small-scale Bioreactors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Small-scale Bioreactors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By End user (Pharmaceutical & Biopharmaceutical Companies, CROs & CMOs, Academic & Research Institutes)
  • 5.2.2. By Product (Reusable Bioreactors( Stainless Steel Bioreactors, Glass Bioreactors), Single-use Bioreactors)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Small-scale Bioreactors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By End user
  • 6.2.2. By Product
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Small-scale Bioreactors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By End user
      • 6.3.1.2.2. By Product
  • 6.3.2. Canada Small-scale Bioreactors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By End user
      • 6.3.2.2.2. By Product
  • 6.3.3. Mexico Small-scale Bioreactors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By End user
      • 6.3.3.2.2. By Product

7. Europe Small-scale Bioreactors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By End user
  • 7.2.2. By Product
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Small-scale Bioreactors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By End user
      • 7.3.1.2.2. By Product
  • 7.3.2. France Small-scale Bioreactors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By End user
      • 7.3.2.2.2. By Product
  • 7.3.3. United Kingdom Small-scale Bioreactors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By End user
      • 7.3.3.2.2. By Product
  • 7.3.4. Italy Small-scale Bioreactors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By End user
      • 7.3.4.2.2. By Product
  • 7.3.5. Spain Small-scale Bioreactors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By End user
      • 7.3.5.2.2. By Product

8. Asia Pacific Small-scale Bioreactors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By End user
  • 8.2.2. By Product
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Small-scale Bioreactors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By End user
      • 8.3.1.2.2. By Product
  • 8.3.2. India Small-scale Bioreactors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By End user
      • 8.3.2.2.2. By Product
  • 8.3.3. Japan Small-scale Bioreactors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By End user
      • 8.3.3.2.2. By Product
  • 8.3.4. South Korea Small-scale Bioreactors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By End user
      • 8.3.4.2.2. By Product
  • 8.3.5. Australia Small-scale Bioreactors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By End user
      • 8.3.5.2.2. By Product

9. Middle East & Africa Small-scale Bioreactors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By End user
  • 9.2.2. By Product
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Small-scale Bioreactors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By End user
      • 9.3.1.2.2. By Product
  • 9.3.2. UAE Small-scale Bioreactors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By End user
      • 9.3.2.2.2. By Product
  • 9.3.3. South Africa Small-scale Bioreactors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By End user
      • 9.3.3.2.2. By Product

10. South America Small-scale Bioreactors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By End user
  • 10.2.2. By Product
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Small-scale Bioreactors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By End user
      • 10.3.1.2.2. By Product
  • 10.3.2. Colombia Small-scale Bioreactors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By End user
      • 10.3.2.2.2. By Product
  • 10.3.3. Argentina Small-scale Bioreactors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By End user
      • 10.3.3.2.2. By Product

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Small-scale Bioreactors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sartorius AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc.
• 15.3. Merck KGaA
• 15.4. Danaher Corp.
• 15.5. Lonza Group Ltd.
• 15.6. Eppendorf SE
• 15.7. Miltenyi Biotec India Pvt Ltd.
• 15.8. Getinge AB
• 15.9. Solaris Biotech USA, Inc.
• 15.10. Infors AG

16. Strategic Recommendations

17. About Us & Disclaimer